Article
Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases
Author/s | Gallego Durán, Rocío
Montero-Vallejo, Rocío Maya Miles, Douglas Lucena, Ana Martin, Franz Ampuero Herrojo, Javier Romero Gómez, Manuel |
Department | Universidad de Sevilla. Departamento de Medicina |
Publication Date | 2021-11-24 |
Deposit Date | 2022-11-24 |
Published in |
|
Abstract | Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has ... Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has displaced viral hepatitis as the main cause of severe forms of hepatic diseases, although the onset and transition of MAFLD stages still remains unclear. Nevertheless, innate and adaptive immune responses seem to play an essential role in the establishment and further progression of this disease. The immune system is responsible of safeguard and preserves organs and systems function, and might be altered under different stimuli. Thus, the liver suffers from metabolic and immune changes leading to different injuries and loss of function. It has been stablished that cell-cell crosstalk is a key process in the hepatic homeostasis maintenance. There is mounting evidence suggesting that MAFLD pathogenesis is determined by a complex interaction of environmental, genetic and host factors that leads to a full plethora of outcomes. Therefore, herein we will revisit and discuss the interplay between immune mechanisms and MAFLD, highlighting the potential role of immunological markers in an attempt to clarify its relationship. |
Funding agencies | Consejería de Salud. Junta de Andalucía PC-0148-2016-0148 Fondo Europeo de Desarrollo Regional (FEDER) en colaboración con la Consejería de Salud de la Junta de Andalucía PE-0451 -2018 Ministerio de Economía y Competitividad AGL2017-86927-R Instituto de Salud Carlos III (PI16/01842, PI19/01404, PI19/00589, IFI18/00041 y CD18/00126) |
Project ID. | PC-0148-2016-0148
PE-0451 -2018 AGL2017-86927-R PI16/01842 PI19/01404 PI19/00589 IFI18/00041 CD18/00126 |
Citation | Gallego Durán, R., Montero-Vallejo, R., Maya Miles, D., Lucena, A., Martin, F., Ampuero Herrojo, J. y Romero Gómez, M. (2021). Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Frontiers in Immunology, 12, 667354. https://doi.org/10.3389/fimmu.2021.667354. |
Files | Size | Format | View | Description |
---|---|---|---|---|
Analysis of Common Pathways and ... | 994.9Kb | [PDF] | View/ | |